Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 4,234 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Study Product Clear all
Withdrawn Phase 2 Interventional

A Study to Investigate Leramistat in Patients With IPF

NCT05951296
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Leramistat, Placebo
Drug
Lead sponsor
Modern Biosciences Ltd
Industry
Eligibility
40 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
21
States / cities
Fresno, California • Denver, Colorado • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Oct 23, 2026, 6:17 PM EDT
Completed Phase 1Phase 2 Interventional

Study of NP002 in Subjects With Idiopathic Parkinson's Disease to Treat Dyskinesias Due to Levodopa Therapy

NCT00957918
View directory record Official record
Conditions
Parkinson's Disease
Interventions
nicotine, placebo comparator
Drug · Other
Lead sponsor
Neuraltus Pharmaceuticals, Inc.
Industry
Eligibility
30 Years to 83 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angelis, California • Oxnard, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2011 · Synced Oct 23, 2026, 6:17 PM EDT
Completed Not applicable Interventional

Use of Technological Advances to Prevent Smoking Relapse Among Smokers With PTSD

NCT01990079
View directory record Official record
Conditions
PTSD, Smoking
Interventions
Bupropion, nicotine replacement therapy, Smoking cessation counseling, mobile contingency management, Stay Quit Coach
Drug · Other · Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 23, 2026, 6:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of B. Adolescentis iVS-1 Probiotic on Gastrointestinal Outcomes

NCT07408518
View directory record Official record
Conditions
Digestive Disease, Gut Health
Interventions
Probiotic, Placebo
Dietary Supplement · Other
Lead sponsor
Synbiotic Health
Industry
Eligibility
18 Years to 75 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 23, 2026, 6:17 PM EDT
Terminated Phase 2 Interventional Results available

Study of the Safety, Tolerability and Efficacy of NP-101 in Treating High Risk Participants Who Are Covid-19 Positive.

NCT05785390
View directory record Official record
Conditions
COVID-19
Interventions
NP-101, Placebo
Drug · Other
Lead sponsor
Novatek Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
Miami, Florida • Berwyn, Illinois • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 23, 2026, 6:17 PM EDT
Terminated Phase 3 Interventional Results available

Clinical Equivalence Study of Fluticasone Propionate Nasal Spray, 50 mcg/Actuation vs. Flonase in Allergic Rhinitis Patients

NCT02246920
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Fluticasone propionate, Flonase®, Placebo
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
12 Years and older
Enrollment
1,474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Oct 23, 2026, 6:17 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

True Functional Restoration and Analgesia in Non-Radicular Low Back Pain

NCT05419297
View directory record Official record
Conditions
Back Pain Lower Back Chronic, Chronic Pain
Interventions
Buprenorphine Buccal Film [Belbuca], Urine Drug Screening, actigraph, PROMIS 29, sit to stand test, numerical rating scale pain score, patient global impression of function, PROMIS - sleep
Drug · Other · Device + 1 more
Lead sponsor
Carolinas Pain Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 23, 2026, 6:17 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Event-Related Potential (ERP) Components in Clinical Diagnosis

NCT05673759
View directory record Official record
Conditions
Alzheimer Disease, Dementia, Mild, Mild Cognitive Impairment
Interventions
Electroencephalogram (EEG) system, Standard Neuropsychological Testing, Additional neuropsychological tests
Device · Behavioral
Lead sponsor
Boston University
Other
Eligibility
20 Years to 90 Years
Enrollment
148 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 23, 2026, 6:17 PM EDT
Terminated Phase 3 Interventional Results available

Open-Label Study to Evaluate the Effect of Treatment With Fentanyl Buccal Tablets on Pain Anxiety Symptoms When Used for the Management of Breakthrough Pain

NCT00387010
View directory record Official record
Conditions
Pain, Chronic Pain, Breakthrough Pain
Interventions
Fentanyl Buccal Tablets
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 80 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
33
States / cities
Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2012 · Synced Oct 23, 2026, 6:17 PM EDT
Completed Phase 3 Interventional Results available

Study of Intra-articular Injections vs Placebo in Patients With Pain From Osteoarthritis of the Knee

NCT01887678
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Traumeel® / Zeel® Injectable Solution, Placebo
Drug
Lead sponsor
Biologische Heilmittel Heel GmbH
Industry
Eligibility
45 Years to 80 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
30
States / cities
Phoenix, Arizona • Tucson, Arizona • Dinuba, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2018 · Synced Oct 23, 2026, 6:17 PM EDT
Completed Phase 2 Interventional Results available

Study of CA-008 (Vocacapsaicin) in Bunionectomy Patients

NCT03599089
View directory record Official record
Conditions
Post-surgical Pain
Interventions
CA-008, Placebo, Ketorolac, Acetaminophen, Oxycodone, Bupivacaine Hydrochloride
Drug
Lead sponsor
Concentric Analgesics
Industry
Eligibility
18 Years to 75 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Pasadena, California • Pasadena, Maryland • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2021 · Synced Oct 23, 2026, 6:17 PM EDT
Completed Not applicable Interventional Results available

A Double-blind Study to Determine if Intraduodenal Indomethacin Can Decrease the Incidence of Post-ERCP Pancreatitis

NCT00727740
View directory record Official record
Conditions
Pancreatitis
Interventions
Indomethacin, Placebo suspension
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Oct 23, 2026, 6:17 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Arms and Hands

NCT00115154
View directory record Official record
Conditions
Keratosis
Interventions
Aldara (imiquimod) cream, 5%
Drug
Lead sponsor
Graceway Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
18
States / cities
Tucson, Arizona • Vista, California • Atlanta, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2007 · Synced Oct 23, 2026, 6:17 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

NCT03937154
View directory record Official record
Conditions
Chemotherapy-induced Thrombocytopenia
Interventions
Romiplostim, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
Ogden, Utah • Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 23, 2026, 6:17 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.1% and RLD in the Treatment of Acne Vulgaris

NCT03427554
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tretinoin cream 0.1%, RETIN-A® Cream, Vehicle of the test product
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
455 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated May 18, 2018 · Synced Oct 23, 2026, 6:17 PM EDT
Recruiting Phase 2 Interventional

Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.

NCT07494305
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
LB-102, Placebo
Drug · Other
Lead sponsor
LB Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
26
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Bellflower, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 23, 2026, 6:17 PM EDT
Completed Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of Topical Minocycline Gel in Patients With Papulopustular Rosacea

NCT03263273
View directory record Official record
Conditions
Rosacea, Papulopustular Rosacea
Interventions
1% Topical Minocycline Gel, 3% Topical Minocycline Gel, Topical Vehicle Gel
Drug · Other
Lead sponsor
Hovione Scientia Limited
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
23
States / cities
Bryant, Arkansas • Rogers, Arkansas • Fremont, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2019 · Synced Oct 23, 2026, 6:17 PM EDT
Completed Phase 2Phase 3 Interventional

To Study the Efficacy & Safety of Oral NA-921 (Bionetide) in Girls and Women with Rett Syndrome

NCT06849973
View directory record Official record
Conditions
Rett Syndrome
Interventions
Drug: Bionetide, Placebo
Drug
Lead sponsor
Biomed Industries, Inc.
Industry
Eligibility
5 Years to 20 Years · Female only
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
12
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Oct 23, 2026, 6:17 PM EDT
Recruiting Phase 2 Interventional

Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment

NCT06955169
View directory record Official record
Conditions
Intracranial Meningioma
Interventions
[177Lu]Lu-DOTATATE, Standard of Care treatments
Drug · Other
Lead sponsor
RTOG Foundation, Inc.
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
17
States / cities
Irvine, California • La Jolla, California • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 23, 2026, 6:17 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment

NCT01087502
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Glimepiride, Placebo, Linagliptin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
16
States / cities
Chula Vista, California • Pembroke Pines, Florida • Decatur, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2014 · Synced Oct 23, 2026, 6:17 PM EDT
Completed Not applicable Interventional

A Study to Compare the Effectiveness of a Four Drug Anti-HIV Regimen Given Alone or in Combination With GM-CSF or IL-12 to HIV-Positive Patients

NCT00000896
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine/Zidovudine, Hepatitis A Vaccine (Inactivated), Interleukin-12, Nevirapine, Stavudine, Sargramostim
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
3
States / cities
San Diego, California • Aurora, Colorado • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 23, 2026, 6:17 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis

NCT02886702
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Tazarotene Cream 0.05%, TAZORAC® (tazarotene) Cream 0.05%, Placebo
Drug
Lead sponsor
Fougera Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
855 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
30
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • Anaheim, California + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 23, 2026, 6:17 PM EDT
Completed Not applicable Interventional

Digital Therapeutic vs Psychoeducation for Management of Mild to Moderate Depression in Adolescents

NCT04985331
View directory record Official record
Conditions
Depression, Teen
Interventions
W-GenZD
Device
Lead sponsor
Woebot Health
Industry
Eligibility
16 Years to 17 Years
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 5, 2022 · Synced Oct 23, 2026, 6:17 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease

NCT05045482
View directory record Official record
Conditions
Hepatic Impairment, Cirrhosis, Cholestatic Liver Disease
Interventions
Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg
Drug
Lead sponsor
Zydus Therapeutics Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 23, 2026, 6:17 PM EDT